Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study of Epcoritamab and Rituximab for First-line Treatment of Follicular Lymphoma

Next Previous
Trial Profile

A Phase 2 Study of Epcoritamab and Rituximab for First-line Treatment of Follicular Lymphoma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 07 Dec 2025 According to the Dana Farber Cancer Institute Media Release, data from this study were presented at the 67th American Society for Hematology Annual Meeting and Exposition from Dec. 6 0-9 in Orlando, FL.
  • 02 Dec 2025 According to a Abbvie media release, data from this trial will be presented at the 2025 American Society of Hematology (ASH) Congress.
  • 03 Jul 2025 Number of treatment arms are increased from 1 to 2 by the addition of Experimental: Epcoritamab + Rituximab Expansion arm. Planned enrolment is also increased, due to the addition of 65 patients of expansion arm.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top